AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31183469 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium evaluation; nearly half of the participants routinely evaluated delirium using the confusion assessment method.
Number of subjects: 429
Study 31183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (25, 50, 75, or 100 mg once daily)
Number of subjects: 21
Study 31183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (continued treatment)
Number of subjects: 21
Study 31183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (discontinued treatment)
Number of subjects: 21
Study 31183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 21
Study 31183813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities
Number of subjects: 21
Study 31183847 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtherapeutic anticoagulation control (≤ 1 episode)
Number of subjects: 760
Study 31183847 — intervention group
Group type: COMPARATOR
Intervention: No subtherapeutic anticoagulation control (control group)
Number of subjects: 760
Study 31183877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (anti-CD47 monoclonal antibody)
Number of subjects: 19
Study 31184558 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive fractional flow reserve (FFR) derived from coronary CT angiography
Number of subjects: 0
Study 31184558 — intervention group
Group type: COMPARATOR
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0
Study 31185256 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ICP monitoring with a parenchymal probe (Camino) and tier-based management algorithm for elevated ICP
Number of subjects: 10
Study 31185735 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal medication escalation
Number of subjects: 901
Study 31185735 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal medication de-escalation
Number of subjects: 901
Study 31185735 — intervention group
Group type: COMPARATOR
Intervention: No change in antianginal medications
Number of subjects: 901
Study 31185735 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalation correlates
Number of subjects: 901
Study 31185735 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation correlates
Number of subjects: 901
Study 31185735 — intervention group
Group type: COMPARATOR
Intervention: Variation in escalation
Number of subjects: 901
Study 31185735 — intervention group
Group type: COMPARATOR
Intervention: Variation in de-escalation
Number of subjects: 901
Study 31185997 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care services (home hospitalization, prehabilitation for major surgery, community-based interventions)
Number of subjects: 520000
Study 31185997 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care services
Number of subjects: 520000
Study 31186258 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 641
Study 31186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab-AVD (doxorubicin, vinblastine, dacarbazine)
Number of subjects: 34
Study 31186274 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab-AVD
Number of subjects: 34
Study 31186669 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-AO-101
Number of subjects: 50
Study 31186669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31187233 — intervention group
Group type: EXPERIMENTAL
Intervention: gFTRD (Ovesco Endoscopy, Tübingen, Germany)
Number of subjects: 29
Study 31187454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month, escalated to 600 or 1200 mg as tolerated.
Number of subjects: 14
Study 31188201 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS 5 (frail)
Number of subjects: 937
Study 31188201 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS 6/7 (severely frail)
Number of subjects: 937
Study 31188201 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty presence (CFS 5-7)
Number of subjects: 937
Study 31188201 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 937
Study 31188201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing frailty
Number of subjects: 937
Study 31188201 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS 5-7 (frail)
Number of subjects: 937
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS
Number of subjects: 50
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS-I
Number of subjects: 50
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS-R-I
Number of subjects: 50
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: Videopupillometry
Number of subjects: 50
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS, NCS-I, NCS-R-I
Number of subjects: 50
Study 31188267 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS-I, NCS-R-I
Number of subjects: 50
Study 31188726 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 95
Study 31188726 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib
Number of subjects: 95
Study 31189036 — intervention group
Group type: EXPERIMENTAL
Intervention: Metagenomic NGS of CSF
Number of subjects: 204
Study 31189036 — intervention group
Group type: COMPARATOR
Intervention: Routine microbiologic testing
Number of subjects: 204
Study 31189377 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention consisting of three workshops
Number of subjects: 407
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV presence and viral load measured via qPCR
Number of subjects: 150
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Local concentrations of cytokines measured via MesoScale Discovery technology
Number of subjects: 150
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune cells measured via flow cytometry
Number of subjects: 150
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbiota sequencing (16S and ITS1 loci)
Number of subjects: 150
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration of circulating anti-HPV antibodies
Number of subjects: 150
Study 31189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-samples for HPV monitoring
Number of subjects: 150
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed ≥48 hours after symptom onset
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed <48 hours after symptom onset
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) in prospective cohort
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed after 48 hours of symptoms' onset in prospective cohort
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration (NA) performed <48 hours after symptoms' onset in prospective cohort
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay between first symptom and NA procedure ≥48 hours
Number of subjects: 217
Study 31189731 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller pneumothorax estimated by Light's index
Number of subjects: 217
Study 31190006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 225 mg/m²
Number of subjects: 0
Study 31190006 — intervention group
Group type: COMPARATOR
Intervention: High-dose melphalan (MEL200)
Number of subjects: 0
Study 31190179 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaders being positive and engaged in the intervention, holding clear goals and visions for the intervention in the clinic.
Number of subjects: 26
Study 31190179 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of outcome monitoring as a resource for practice improvement.
Number of subjects: 26
Study 31190276 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Number of subjects: 0
Study 31190276 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.1 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Number of subjects: 0
Study 31190298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin (IV) administered at an average daily dose of 13.7±3.5 g over 12.4±8.6 days, almost exclusively in combination with other antibiotics.
Number of subjects: 209
Study 31190584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0
Study 31191000 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Inflammatory Index (CII) based on neutrophil-to-lymphocyte ratio and lactate dehydrogenase
Number of subjects: 0
Study 31191000 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31191007 — intervention group
Group type: EXPERIMENTAL
Intervention: Simotinib, a novel specific EGFR tyrosine kinase inhibitor, dosage and duration not specified.
Number of subjects: 0
Study 31191190 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet (PBD)
Number of subjects: 36
Study 31191235 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) - 20 daily sessions, 1 mA, 20 min, 4 mm ring radius.
Number of subjects: 1
Study 31191235 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements prior to intervention.
Number of subjects: 1
Study 31191688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cells from the acetabulum
Number of subjects: 3
Study 31191688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cells from the bone marrow
Number of subjects: 3
Study 31191688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cells from the femur
Number of subjects: 3
Study 31191688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cells
Number of subjects: 3
Study 31191908 — intervention group
Group type: EXPERIMENTAL
Intervention: Active knowledge translation intervention including the addition of the Kidney Failure Risk Equation (KFRE) and decision aids to clinics' Data Presentation Tool (DPT), patient-facing visual aids, a medical detailing visit, and sentinel feedback reports.
Number of subjects: 32
Study 31191908 — intervention group
Group type: COMPARATOR
Intervention: Control group exposed only to current guidelines for CKD management, without active dissemination.
Number of subjects: 32
Study 31191908 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys administered in the clinic post-visit to measure CKD-specific health literacy and trust in physician care.
Number of subjects: 32
Study 31191908 — intervention group
Group type: EXPERIMENTAL
Intervention: At the provider level, measuring satisfaction with the risk prediction tools.
Number of subjects: 32
Study 31191908 — intervention group
Group type: EXPERIMENTAL
Intervention: At the health system level, assessing cost of CKD care and appropriate referrals for patients at high risk of kidney failure based on provincial guidelines.
Number of subjects: 32
Study 31191965 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic players with long-standing groin pain
Number of subjects: 102
Study 31191965 — intervention group
Group type: COMPARATOR
Intervention: Controls (age-matched, asymptomatic)
Number of subjects: 102
Study 31191965 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic players with groin pain
Number of subjects: 102
Study 31191990 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling with inverted flap technique
Number of subjects: 7
Study 31192894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Oral TDF/FTC PrEP
Number of subjects: 0
Study 31192894 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31192910 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification protocols and clinical, physical, and biochemical parameters
Number of subjects: 44
Study 31192910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, physical, and biochemical parameters measured before and after CRP
Number of subjects: 44
Study 31192960 — intervention group
Group type: EXPERIMENTAL
Intervention: BCQ assessment and glycoproteomics approach
Number of subjects: 6
Study 31192960 — intervention group
Group type: COMPARATOR
Intervention: BCQ assessment
Number of subjects: 6
Study 31193095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at weight reduction
Number of subjects: 15269
Study 31193095 — intervention group
Group type: COMPARATOR
Intervention: Medical nutrition therapy
Number of subjects: 15269
Study 31193095 — intervention group
Group type: COMPARATOR
Intervention: Mail/telephone outreach
Number of subjects: 15269
Study 31193095 — intervention group
Group type: COMPARATOR
Intervention: Media/advertising
Number of subjects: 15269
Study 31193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) incidence
Number of subjects: 391
Study 31193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia (PHN) incidence
Number of subjects: 391
Study 31193334 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-positive patients
Number of subjects: 148
Study 31193334 — intervention group
Group type: EXPERIMENTAL
Intervention: ε4 homozygous or amyloid-positive patients
Number of subjects: 148
Study 31193334 — intervention group
Group type: EXPERIMENTAL
Intervention: ε4 homozygous, family history-positive, or amyloid-positive patients
Number of subjects: 148
Study 31193334 — intervention group
Group type: COMPARATOR
Intervention: Unenriched patients
Number of subjects: 148
Study 31193477 — intervention group
Group type: EXPERIMENTAL
Intervention: AV2
Number of subjects: 327
Study 31193477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 31193580 — intervention group
Group type: COMPARATOR
Intervention: Centralized vaccine reminder/recall (R/R) via autodialed telephone and mail, up to 3 reminders.
Number of subjects: 15769
Study 31193580 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care (control group).
Number of subjects: 15769
Study 31193613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prophylactic intravenous hydration
Number of subjects: 660
Study 31193613 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 660
Study 31193620 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose mebendazole
Number of subjects: 185
Study 31193620 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose mebendazole
Number of subjects: 185
Study 31193636 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based event recorder (AliveCor) alongside standard care
Number of subjects: 243
Study 31193636 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 243
Study 31193674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dose of multi-OIT
Number of subjects: 70
Study 31193674 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dose of multi-OIT
Number of subjects: 70
Study 31193674 — intervention group
Group type: COMPARATOR
Intervention: 0 mg dose (discontinuation of multi-OIT)
Number of subjects: 70
Study 31193824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 231
Study 31193824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 31193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge smoking cessation intervention
Number of subjects: 942
Study 31193919 — intervention group
Group type: COMPARATOR
Intervention: Tobacco use during hospitalization
Number of subjects: 942
Study 31194225 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg orally once daily plus Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Number of subjects: 55
Study 31194225 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab
Number of subjects: 55
Study 31194228 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg orally once daily and Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Number of subjects: 62
Study 31194228 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib in combination with Pembrolizumab
Number of subjects: 62
Study 31194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 617
Study 31194247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 31194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 617
Study 31194611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in cohort A (untreated brain metastases)
Number of subjects: 73
Study 31194611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in cohort B (prior therapy)
Number of subjects: 73
Study 31194748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) patients
Number of subjects: 102
Study 31194748 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cystic fibrosis (non-CF) patients
Number of subjects: 102
Study 31194748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 31194748 — intervention group
Group type: EXPERIMENTAL
Intervention: CT score
Number of subjects: 102
Study 31194764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (PEX)
Number of subjects: 932
Study 31194764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus testosterone (TEX)
Number of subjects: 932
Study 31194764 — intervention group
Group type: COMPARATOR
Intervention: HDBR alone (CON)
Number of subjects: 932
Study 31194872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 to 0.16 mg/kg) for 12 months
Number of subjects: 29
Study 31194884 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 1100
Study 31194939 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily food choices
Number of subjects: 34
Study 31194939 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotonous diet (meal replacement beverages)
Number of subjects: 34
Study 31194939 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dietary diversity
Number of subjects: 34
Study 31195062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks
Number of subjects: 59
Study 31195984 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) measurement
Number of subjects: 306
Study 31195984 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT/SMT ratio measurement
Number of subjects: 306
Study 31195984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic scores (APACHE-II, Ranson's, BISAP, SIRS)
Number of subjects: 306
Study 31195984 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT measurement
Number of subjects: 306
Study 31195991 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of aberrant methylation of ctDNA
Number of subjects: 0
Study 31195991 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of mutations in ctDNA
Number of subjects: 0
Study 31195996 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m²
Number of subjects: 108
Study 31195996 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² + Trastuzumab
Number of subjects: 108
Study 31195996 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires assessing medication adherence (CQR)
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about Medicines Questionnaire (BMQ)
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Information about Medicines Scale (SIMS)
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol five-dimensions (EQ5D)
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Lupus International Collaborating Clinics (SLICC)
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 210
Study 31196083 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of NSAID
Number of subjects: 210
Study 31196179 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid biomarkers (sVCAM-1 and MMP-3)
Number of subjects: 25
Study 31196179 — intervention group
Group type: EXPERIMENTAL
Intervention: Six OA-related SF biomarkers
Number of subjects: 25
Study 31196203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM) catheter
Number of subjects: 20
Study 31196203 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon catheter
Number of subjects: 20
Study 31196680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 706
Study 31196892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy
Number of subjects: 0
Study 31196903 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anthropometrical measures, puberty development, nutritional biomarkers, symptoms of depression, anxiety, and trauma using validated scales.
Number of subjects: 1425
Study 31197640 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-logistic model applied in clinical trials
Number of subjects: 0
Study 31197640 — intervention group
Group type: EXPERIMENTAL
Intervention: Best dropout model (log-logistic) incorporated in the final two-state model
Number of subjects: 0
Study 31197640 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial simulation
Number of subjects: 0
Study 31197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (distal pancreatectomy, Whipple, total pancreatectomy)
Number of subjects: 354
Study 31197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 354
Study 31198061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography (EEG) monitoring
Number of subjects: 152
Study 31198061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography background features
Number of subjects: 152